Palvella Therapeutics (PVLA) Return on Capital Employed (2014 - 2026)
Palvella Therapeutics' (PVLA) quarterly Return on Capital Employed came in at 29.88% in Q1 2026, down 289.0% year-on-year from 15.81% in Q1 2025, and up 59.82% on a QoQ basis from 74.37% in Q4 2025.
Palvella Therapeutics (PVLA) Return on Capital Employed (2014 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 13 years of Return on Capital Employed data on file, last reported at 29.88% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 289.0% year-over-year to 29.88% in Q1 2026; TTM through Mar 2026 was 29.88%, a 289.0% decrease from a year earlier, with the FY2025 full-year figure at 61.71%, down 2240.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 29.88%, up from 74.37% in the prior quarter.
- Over the last five years, Return on Capital Employed for PVLA reached as high as 19.73% in Q3 2024 and fell as low as 112.02% in Q1 2023.
- Historically, Return on Capital Employed has averaged 45.74% across 5 years, with a median of 51.23% in 2022.
- Across the five-year window, Return on Capital Employed surged 12915 bps in 2024 and plunged 7248 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 71.57% in 2022, then surged by 47 bps to 38.16% in 2023, then grew by 13 bps to 33.29% in 2024, then sank by 123 bps to 74.37% in 2025, then soared by 60 bps to 29.88% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 29.88% in Q1 2026, 74.37% in Q4 2025, and 52.75% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Palvella Therapeutics | 318.78 Mn | 56.92 Mn | - | -29.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.88% |
| Dec 31, 2025 | -74.37% |
| Sep 30, 2025 | -52.75% |
| Jun 30, 2025 | -39.64% |
| Mar 31, 2025 | -27.00% |
| Dec 31, 2024 | -33.29% |
| Sep 30, 2024 | 19.73% |
| Jun 30, 2024 | -14.76% |
| Mar 31, 2024 | 17.13% |
| Dec 31, 2023 | -38.16% |
| Sep 30, 2023 | -82.46% |
| Jun 30, 2023 | -73.49% |
| Mar 31, 2023 | -112.02% |
| Dec 31, 2022 | -71.57% |
| Sep 30, 2022 | -58.67% |
| Jun 30, 2022 | -55.23% |
| Mar 31, 2022 | -51.23% |
| Dec 31, 2021 | -47.85% |
| Sep 30, 2021 | -48.44% |
| Jun 30, 2021 | -51.63% |